Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07592000 · ClinicalTrials.gov registry record · Phase 1
Breakthrough - T1DM and Chronic Kidney Disease
A Phase 1 study, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT07592000 is a Phase 1 study that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 10 participants.
The verdict
NCT07592000, a Phase 1 study, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).
Interventions
- BIOLOGICAL Islet Cell Transplant
- DRUG Tegoprubart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2027-04-29 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07592000
The ClinicalTrials.gov registry entry for NCT07592000 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Islet Cell Transplant is the first listed.
NCT07592000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07592000 about?
NCT07592000 is a clinical study titled "Breakthrough - T1DM and Chronic Kidney Disease". Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both ...
What is the current status of trial NCT07592000?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2027-04-29. Estimated completion is 2030-01-31.
What interventions are being tested in trial NCT07592000?
The interventions under investigation include: Islet Cell Transplant (BIOLOGICAL), Tegoprubart (DRUG).
Who is sponsoring clinical trial NCT07592000?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.